IL-6: Relevance for immunopathology of SARS-CoV-2.Cytokine Growth Factor Rev. 2020 06; 53:13-24.CG
Abstract
COVID-19 mortality is strongly associated with the development of severe pneumonia and acute respiratory distress syndrome with the worst outcome resulting in cytokine release syndrome and multiorgan failure. It is becoming critically important to identify at the early stage of the infection those patients who are prone to develop the most adverse effects. Elevated systemic interleukin-6 levels in patients with COVID-19 are considered as a relevant parameter in predicting most severe course of disease and the need for intensive care. This review discusses the mechanisms by which IL-6 may possibly contribute to disease exacerbation and the potential of therapeutic approaches based on anti-IL-6 biologics.
Links
MeSH
Pub Type(s)
Journal Article
Research Support, Non-U.S. Gov't
Review
Language
eng
PubMed ID
32475759
Citation
Gubernatorova, E O., et al. "IL-6: Relevance for Immunopathology of SARS-CoV-2." Cytokine & Growth Factor Reviews, vol. 53, 2020, pp. 13-24.
Gubernatorova EO, Gorshkova EA, Polinova AI, et al. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13-24.
Gubernatorova, E. O., Gorshkova, E. A., Polinova, A. I., & Drutskaya, M. S. (2020). IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine & Growth Factor Reviews, 53, 13-24. https://doi.org/10.1016/j.cytogfr.2020.05.009
Gubernatorova EO, et al. IL-6: Relevance for Immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13-24. PubMed PMID: 32475759.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - IL-6: Relevance for immunopathology of SARS-CoV-2.
AU - Gubernatorova,E O,
AU - Gorshkova,E A,
AU - Polinova,A I,
AU - Drutskaya,M S,
Y1 - 2020/05/20/
PY - 2020/05/16/received
PY - 2020/05/17/accepted
PY - 2020/6/2/pubmed
PY - 2020/7/1/medline
PY - 2020/6/2/entrez
KW - Anti-cytokine therapeutics
KW - Cytokine release syndrome
KW - IL-6
KW - SARS-CoV-2
SP - 13
EP - 24
JF - Cytokine & growth factor reviews
JO - Cytokine Growth Factor Rev
VL - 53
N2 - COVID-19 mortality is strongly associated with the development of severe pneumonia and acute respiratory distress syndrome with the worst outcome resulting in cytokine release syndrome and multiorgan failure. It is becoming critically important to identify at the early stage of the infection those patients who are prone to develop the most adverse effects. Elevated systemic interleukin-6 levels in patients with COVID-19 are considered as a relevant parameter in predicting most severe course of disease and the need for intensive care. This review discusses the mechanisms by which IL-6 may possibly contribute to disease exacerbation and the potential of therapeutic approaches based on anti-IL-6 biologics.
SN - 1879-0305
UR - https://www.unboundmedicine.com/medline/citation/32475759/IL_6:_Relevance_for_immunopathology_of_SARS_CoV_2_
DB - PRIME
DP - Unbound Medicine
ER -